FDA Generics Office Drinks Super Serum, Then Shrinks
Executive Summary
OGD sheds almost half its staff as part of an organizational elevation.
You may also be interested in...
New Name, Old Problems: US FDA’s Cell And Gene Therapy Office Still Facing Growth Challenges
The group will be called the Office of Therapeutic Products, but needs more people to handle its increasing workload.
US FDA Elevates Controlled Substances Coordinator To New Deputy CDER Director Role
The move should increase the visibility of the FDA’s wide-ranging, and widely criticized, opioid epidemic response.
Generics Office At US FDA Could Get New Director Before Uhl Departs
Kathleen Uhl gave seven months' notice of her retirement, which may allow new director to be hired and on-boarded before she departs.